Your browser doesn't support javascript.
loading
Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia.
Tanneru, Karthik; Gautam, Shiva; Norez, Daniel; Kumar, Jatinder; Alam, Muhammad Umar; Koocheckpour, Shahriar; Balaji, K C; Joseph, Costa.
Afiliação
  • Tanneru K; Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA.
  • Gautam S; Department of Biostatistics, University of Florida, Jacksonville, FL, USA.
  • Norez D; Department of Biostatistics, University of Florida, Jacksonville, FL, USA.
  • Kumar J; Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA.
  • Alam MU; Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA.
  • Koocheckpour S; Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA.
  • Balaji KC; Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA.
  • Joseph C; Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA. joseph.costa@jax.ufl.edu.
Int Urol Nephrol ; 52(6): 999-1008, 2020 Jun.
Article em En | MEDLINE | ID: mdl-32065331
BACKGROUND: Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results. METHODS: We performed a critical review in according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. From a total 768 published articles that matched our search terms, 5 studies with minimum follow-up of 24 months were selected for comparison and data analyzed in terms of baseline characteristics, functional, and sexual health outcomes. RESULTS: Included in the analyses are five studies with a minimum follow-up of 24 months. A total of 386 patients underwent PUL and 322 patients (83.4%) are available for follow-up at 24 months. The randomized studies are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Qmax) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups. CONCLUSION: PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hiperplasia Prostática / Uretra Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Limite: Humans / Male Idioma: En Revista: Int Urol Nephrol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hiperplasia Prostática / Uretra Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Limite: Humans / Male Idioma: En Revista: Int Urol Nephrol Ano de publicação: 2020 Tipo de documento: Article